Welcome to Icon Bioscience, Inc. 

Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary drug delivery platform, Verisome®.

IBI’s Verisome drug delivery technology is the most advanced, yet simplest system for controlling the release of intraocular therapeutic agents in the eye for extended periods of time. Its unmatched versatility can support products individually formulated to meet the specific clinical requirements of a given active agent targeting a specific ophthalmic disease.

IBI’s two lead portfolio products are currently in clinical trials with respective New Drug Application (NDA) submissions targeted for 2012 and 2014. Three additional products are scheduled to begin clinical trials in 2012 and 2013.  IBI has also executed agreements with several global pharmaceutical companies for multiple research programs.